Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Clinical evidence

REVEAL pivotal

57 evidence topics · 19 sources

Objective
Location and study date
Registered sites for NCT05606614 (Parts A and B combined)
SiteRegistry record
Duarte, California, United States“City of Hope”
La Jolla, California, United States“UC San Diego”
Oakland, California, United States“UC San Francisco Benioff Children's Hospital”
Chicago, Illinois, United States“Rush University Medical Center”
Baltimore, Maryland, United States“Kennedy Krieger Institute”
Boston, Massachusetts, United States“Boston Children's Hospital”
St Louis, Missouri, United States“Washington University, St. Louis”
Dallas, Texas, United States“UT Southwestern Children's Medical Center”
Montreal, Quebec, Canada“CHU St. Justine”
Study design
Eligibility criteria
Registered inclusion and exclusion criteria
Treatment
Study outcomes
Rationale for using Rett syndrome developmental milestone assessment response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design and comparator: REVEAL Pivotal is a single-arm, open-label trial with no concurrent control. Efficacy is judged against an external null response rate of 6.7% (1 of 15 participants) derived from the Rett Syndrome Natural History Study, with a 33% response rate (5 of 15) as the minimum threshold for success. The natural history analysis cites sham lumbar puncture, functional unblinding from required immunosuppression, and delayed treatment as ethical and methodological obstacles to a controlled design.
  • Derivation of the null: the 28 milestones, the minimum age of 6 years, the time-since-loss rules, and the 6.7% threshold come from analyses of Rett Syndrome Natural History Study data. The highest spontaneous gain rate observed after 6 years of age was 3%, corresponding to 0.45 expected spontaneous responders among 15 participants, and one spontaneous responder (6.7%) was selected as the null threshold because the responder count must be discrete.
  • Baseline and milestone eligibility: a milestone is eligible for gain or regain when medical history confirms that it was never achieved or was lost sufficiently long ago and an in-clinic video assessment confirms that it is not demonstrated. In the RESUME validation study, agreement between the RS-DMA historical caregiver interview and the performative RS-DMA averaged 81.8%, with more than one-third of items at slight or fair agreement.
  • Endpoint validation: the RS-DMA was validated in a non-interventional study of 13 participants. Inter-rater agreement was substantial to excellent for 27 of the 28 milestones and fair for identifying body parts, and 83% of video recordings were rated feasible for central rating. A responder is a participant who gains or regains at least 1 of 28 milestones, so a single milestone of any type meets the definition.
  • Blinding and assessment: only central raters are masked, and only to the timing of each video. Milestone demonstration is a performed task administered in clinic. The 2025 FDA draft guidance states that self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals and the intervention is expected to lead to improvement, and that objectively measured endpoints that are not effort-dependent are critical to interpreting self-controlled or other non-blinded trials. The natural history data describe a developmental plateau from 6 years of age and slow loss of gross motor skills during Stage III.
  • Secondary endpoints: the key secondary measures are the R-MBA and CGI-I. One publication describes the reliability, validity, and responsiveness profiles of the outcome measures it assessed as mostly incomplete, with no data on meaningful change, and the psychometric study of the clinician-reported MBA called for longitudinal evaluation of the measure.
  • Size, timing, and analysis: 17 females aged 6 to under 22 years were dosed against a planned 15. A BLA may rest on a 6-month interim analysis, while the registered primary outcome runs from baseline through week 52 and the statistical analysis plan names a 12-month primary analysis. The registered primary outcome is worded as a change from baseline in the percentage of responders, which differs from the response rate the sponsor describes. No published protocol or statistical analysis plan was identified.
  • Population and extrapolation: eligibility is limited to females with classic Rett syndrome and a loss-of-function MECP2 variant, excluding atypical Rett syndrome and participants needing invasive ventilation. The sponsor plans to extrapolate efficacy to children aged 2 to under 6 years, an age range in which the natural history analysis reports spontaneous first-time gain of a single milestone as high as 97%.
  • Results and safety reporting: no efficacy results have been reported; topline interim data are expected in the first half of 2027. Safety has been reported in company filings and press releases, mostly pooled with the phase 1/2 and ASPIRE trials (33 participants). One pivotal participant had a treatment-related Grade 2 serious adverse event of peripheral sensory neuropathy about 6 weeks after dosing in July 2026; no adverse event table specific to the pivotal trial was identified.
  • Reporting consistency: the third quarter 2026 Form 10-Q states that the pivotal trial is taking place in the United States, while the combined registry record lists a site in Montreal and the sponsor reported a No Objection Letter from Health Canada before site activation.